恩替卡韦、替比夫定对乙肝肝硬化代偿期患者血清CAl25、CEA水平影响对比

Effect comparison of entecavir and telbivudine on serum CA125, CEA levels of patients with hep- atitis B compensated liver cirrhosis phase

目的对比恩替卡韦、替比夫定对乙肝肝硬化代偿期患者血清CAl25、CEA水平的影响。方法选择商丘市传染病医院2011年1月至2013年1月收治的50例乙肝肝硬化代偿期患者为研究对象，随机将其分为两组，每组25例，A组行恩替卡韦治疗，B组给予替比夫定治疗，比较两组患者治疗前后CAl25、CEA、肝功能水平及HBV-DNA水平。结果两组治疗前后白蛋白、门冬氯酸转氨酶、总胆红素比较差异均有统计学意义（P〈0．05），但组间比较差异未见统计学意义（P〉0．05）。两组治疗前后HBV-DNA、CAl25及CEA比较差异均有统计学意义（P〈0．05），但组间比较差异未见统计学意义（P〉0．05）。A组HBV-DNA阴转率为84％，B组为88％。结论恩替卡韦、替比夫定均能有效改善乙肝肝硬化代偿期患者肝功能及CAl25、CEA水平，HBV-DNA阴转率无明显差异。

Objective To compare the effects of entecavir and telbivudine on CA125, CEA lev- els of patients with hepatitis H cirrhosis at compensated phase. Methods Fifty patients with hepatitis B cirrhosis compensated period from January 2011 to January 2013 were selected as the research objects and randomly divided into group A and group B, with 25 cases in each group. Group A received entecavir treat- ment and group B received telbivudine treatment. CA125, CEA, liver function and HBV DNA levels, be- fore and after treatment of two groups were compared. Results ALB, AST, TBIL of the two groups before and after treatment were all significantly different （P 〈 0. 05 ）, but the differences among groups were not significant （P 〉 0. 05）. HBV - DNA, CA125 and CEA before and after treatment were all significantly dif- ferent （P 〈 0. 05）, but the differences among groups were also not significant （P 〉 0. 05）. The rate of se- roconversion of HBV-DNA in group A was 84% and 88% in group B. Conclusions Entecavir and telbi- vudine can effectively improve liver function in patients with hepatitis B in cirrhosis compensated period and the level of CA125 and CEA. The rate of HBV-DNA seroconversion has no significant difference.